DRKS00000389已完成4 期
Three-armed study for therapy of primary and secondary syphilis in HIV infection
St. Josef HospitalInterdisziplinäre Immunologische Ambulanz0 个研究点目标入组 115 人开始时间: 2010年5月25日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •HIV positive Patients with serologically proven early syphilis
排除标准
- •-known sensibilization agaist ß-lactam antibiotics
- •-patients that were treated within the last 48h with an agent that is active against treponema pallidum
- •-pregnant or lactating women
- •-patients with late syphilis (latent syphilis of unknown duration, tertiary syphilis or neuro syphilis
研究者
相似试验
招募中
3 期
A phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil (DCF) vs definitive chemoradiotherapy for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus(JCOG1510,TRIANgLE)locally advanced unresectable squamous cell carcinoma of the thoracic esophagusJPRN-UMIN000031165Japan Clinical Oncology Group (JCOG)230
已完成
2 期
Phase II Study of a Quadruple-modality Therapy for Resectable Stage Discrete N2 III A-B Non-small Cell Lung Cancer (WJOG12119L: SQUAT trial)JPRN-jRCT2080224981Tetsuya Mitsudomi (Coordinating Investigator)31
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-BEPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
不适用
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-FRPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 16.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-ITPharma Mar S.A. Sociedad Unipersonal120